ESMO: Padcev/Keytruda Combo Edges Closer To First-Line Bladder Cancer Filing

Big Boost For Seagen

 
• By Kevin Grogan
First-line approval is the target for Padcev/Keytruda combo • Source: Shutterstock

More from Clinical Trials

More from R&D